We are live on ! Find out more
AKCA

Akcea Therapeutics Inc
AKCA

Delisted

AKCA was delisted on the 9th of October, 2020.

56 hedge funds and large institutions have $541M invested in Akcea Therapeutics Inc in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more call options, than puts

Call options by funds: $3.19M | Put options by funds: $2.42M

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

3% more capital invested

Capital invested by funds: $526M → $541M (+$14.9M)

2% less funds holding

Funds holding: 5756 (-1)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
56
Holders Change
-1
Holders Change %
-1.75%
% of All Funds
1.28%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
23
Reduced
18
Closed
9
Calls
$3.19M
Puts
$2.42M
Net Calls
+$774K
Net Calls Change
+$537K

AKCA Hedge Fund Activity: Q2 2018 in Review

56 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q2 2018, worth a combined $541M — up 2.8% from $526M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of AKCA and 8 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 23 added.

The largest buyer was Fidelity Investments, adding an estimated $58.4M. The largest seller was Wellington Management Group, cutting an estimated $18.6M.

  • 56 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q2 2018, down from 57 in Q1 2018.
  • Funds reported $541M of Akcea Therapeutics Inc stock for Q2 2018, up 2.8% quarter-over-quarter.
  • 8 funds opened new Akcea Therapeutics Inc positions in Q2 2018 and 9 closed out, a net change of -1 holder.
  • The largest Akcea Therapeutics Inc buyer in Q2 2018 was Fidelity Investments, an estimated $58.4M added.
  • The largest Akcea Therapeutics Inc seller in Q2 2018 was Wellington Management Group, an estimated $18.6M sold.

Based on aggregated 13F filings for Q2 2018.